GENENTECH INC

• ENSPRYNGAug 14, 2020
• POLIVYJun 10, 2019
• GAZYVANov 1, 2013
• KADCYLAFeb 22, 2013
• PERJETAJun 8, 2012
• ERIVEDGEJan 30, 2012
• ACTEMRAJan 8, 2010
• LUCENTISJun 30, 2006

• Phase 3Active Not Recruitingreadout ~2025-07-16
  A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
• Phase 1Active Not Recruitingreadout ~2026-06-15
  An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
• Phase 1Recruitingreadout ~2026-09-05
  A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
• Phase 2Active Not Recruitingreadout ~2026-10-31
  A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
• Phase 2Recruitingreadout ~2026-11-30
  A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
• Phase 4Active Not Recruitingreadout ~2026-12-31
  Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
• Phase 1/2Active Not Recruitingreadout ~2027-04-30
  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
• Phase 1Recruitingreadout ~2027-06-30
  A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

• Director / officer changeMar 26, 2009
• Other material eventMar 20, 2009
• Entered a material agreement · Modified shareholder rights · Other material eventMar 16, 2009
• Director / officer changeFeb 19, 2009
• Other material eventJan 21, 2009
• Results of operations · Other material eventJan 15, 2009
• Other material eventNov 21, 2008
• Results of operations · Other material eventOct 14, 2008

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.